Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleniglipron in Type 2 Diabetes Mellitus with Obesity or Overweight
NCT07400588Phase 2Completed
- Sponsor
- Gasherbrum Bio
- Start
- Dec 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aleniglipron in type 2 diabetes mellitus (T2DM), obesity, sponsored by Gasherbrum Bio. Started Dec 2025; status: completed.
02
Drugs
aleniglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07400588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07400588.